SecBot SecBot
424B5 ·Filed Jun 10, 2026

TNGX

Tango Therapeutics, Inc.
MIXED
Impact 6/10
Horizonweeks Processed5mo ago SEC0001193125-26-266074
Notable filing: 424B5
Actionable Insight ◆ Mixed

The offering is a clear negative for near-term price action due to ~12.6% immediate dilution and a 5% discount placement. However, the extremely strong clinical data (92% ORR) and the $567M cash infusion that extends runway into 2030 to fund a Phase 3 pivotal trial create a strong bull case medium-term. Traders should expect a gap-down at the open on June 11 (closing date), but watch for buying into weakness if the trial data narrative remains intact. The 60-day insider lock-up limits secondary selling pressure.

DirectionMixed
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$29.82
T+0 close · Jun 10, 2026 · via day close
Latest settled
−23.88%
T+60 · $22.70
Vs SPY
−27.70%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 11 $29.82entry
  2. T+1 · 5mo ago +3.76%α +3.21% · $30.94
  3. T+5 · 5mo ago +8.28%α +7.85% · $32.29
  4. T+20 · 4mo ago +2.35%α +0.46% · $30.52
  5. T+60 · 2mo ago −23.88%α −27.70% · $22.70
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Tango Therapeutics is raising approximately $566.5 million in net proceeds through a public offering of 18,166,667 shares of common stock at $30.00 per share and pre-funded warrants to purchase 1,833,395 shares. The offering priced at a 4.9% discount to the prior closing price of $31.56, resulting in immediate and substantial dilution of $24.10 per share to new investors. The capital raise follows highly positive Phase 1/2 clinical data for its lead candidate vopimetostat in combination with RAS inhibitors, showing a 92% objective response rate in pancreatic cancer, which positioned the company to advance into Phase 3 development. The proceeds are expected to fund operations into 2030 including a pivotal trial and potential commercialization. The large dilutive offering paired with very strong clinical data creates a mixed signal for the stock.

Key Facts

  • Offering of 18,166,667 shares of common stock at $30.00 per share
  • Pre-funded warrants to purchase 1,833,395 shares at $29.999 per warrant
  • Net proceeds of approximately $566.5 million ($651.6 million if underwriters exercise full option for 3,000,009 additional shares)
  • Offering price at a ~4.9% discount to last sale of $31.56 on June 9, 2026
  • Immediate dilution of $24.10 per share to new investors based on net tangible book value
  • As adjusted net tangible book value of $5.90 per share post-offering vs offering price of $30.00
  • Proceeds expected to fund operations into 2030, including pivotal Phase 3 trial for vopimetostat
  • Follows June 8, 2026 data showing 92% ORR in PDAC with daraxonrasib combination and plans to initiate Phase 3
  • Underwriters granted 30-day option for additional shares up to 15% of offering
  • Insiders and company subject to 60-day lock-up
  • ATM facility for up to $35.6 million remains available after lock-up expiration

Financial Impact

~$567M gross capital raise at ~5% discount to market, resulting in ~12.6% dilution to existing shareholders (18.2M new shares vs 144.2M pre-offering outstanding); underwriter fees of ~$33M

dilutionshares outstandingnet tangible book valuecash position

Risk Factors

  • Immediate dilution of ~12.6% to existing shareholders
  • Offering priced at discount to last closing price may pressure stock near-term
  • Clinical-stage biotech with no approved products or current revenue
  • No clinical trial supply agreement in place yet for Phase 3 daraxonrasib combination
  • Dependence on third-party collaborators for drug supply (Revolution Medicines, Erasca)

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
78% bullish (18 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
424B5 Filing (Primary)0001193125-26-266074
Document: d151329dexfilingfees.htm0001193125-26-266074
Document: 0001193125-26-266074-index-headers.html0001193125-26-266074
Document: 0001193125-26-266074-index.html0001193125-26-266074
Document: 0001193125-26-266074.txt0001193125-26-266074

Track record

27 reports on TNGX

Performance horizon

3 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +29.28% at T+60 after the Jun 8, 2026 report. 5 of 8 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $24.22 Now $24.17 +0.21% settles Feb 16
  2. Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $24.50 Now $24.17 +1.35% settles Feb 12
  3. Nov 9, 20267d ago Press Release Neutral 5/10 Entry $22.74 Now $24.17 +6.29% settles Feb 5
  4. Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $21.50 Now $24.17 +12.42% settles Feb 4
  5. Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $20.87 Now $24.17 +15.81% settles Feb 3
  6. Nov 2, 202614d ago Institutional Cluster Neutral 2/10 Entry $23.17 Now $24.17 +4.32% settles Feb 1
  7. Nov 2, 202614d ago 144 Neutral 2/10 Entry $23.17 Now $24.17 +4.32% settles Feb 1
  8. Oct 23, 202624d ago 8-K Bullish 7/10 Entry $23.34 Now $24.17 +3.56% settles Jan 21
  9. Aug 11, 202613w ago 8-K Bearish 6/10 Entry $25.58 to $23.18 Now $24.17 +5.51% ▲ +9.38% +4.51% vs SPY
  10. Aug 11, 202613w ago 8-K Bullish 7/10 No price data
Showing 10 of 27

US Market Status

Market Closed · Opens in 9h 16m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 10, 2026